United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
528.47
-1.06 (-0.20%)
Jul 24, 2026, 4:00 PM EDT - Market closed

United Therapeutics Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, United Therapeutics stock has a consensus rating of "Buy" and an average price target of $663.23. The average 1-year stock price forecast is 25.50% higher than the current stock price, while the lowest is $516 (-2.36%) and the highest is $750 (+41.92%).

Price Target: $663.23 (+25.50%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$516$663.23$687$750
Change-2.36%+25.50%+30.00%+41.92%

Analyst Ratings

The average analyst rating for United Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingFeb '26Mar '26Apr '26May '26Jun '26Jul '26
Strong Buy999999
Buy112333
Hold444333
Sell000000
Strong Sell000000
Total141415151515

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
J.P. Morgan
J.P. Morgan
Buy
Maintains
$687
BuyMaintains$687+30.00%Jul 23, 2026
Jefferies
Jefferies
Buy
Maintains
$733$714
BuyMaintains$733$714+35.11%Jul 10, 2026
Bank of America Securities
Bank of America Securities
Hold
Reiterates
$620$613
HoldReiterates$620$613+16.00%Jul 10, 2026
RBC Capital
RBC Capital
Buy
Maintains
$701$704
BuyMaintains$701$704+33.21%Jul 7, 2026
Leerink Partners
Leerink Partners
Buy
Maintains
n/a
BuyMaintainsn/an/aJun 29, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
3.24B
from 3.18B
Increased by 1.67%
Revenue Next Year
3.68B
from 3.24B
Increased by 13.73%
EPS This Year
27.50
from 27.86
Decreased by -1.28%
EPS Next Year
33.03
from 27.50
Increased by 20.10%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
1.69B1.94B2.33B2.88B3.18B3.24B
Revenue Growth
13.63%14.88%20.20%23.63%10.61%1.67%
Gross Profit
1.56B1.78B2.07B2.57B2.80B2.81B
Gross Margin
92.73%92.17%88.94%89.24%87.92%86.93%
Operating Income
686.90M989.00M1.19B1.45B1.52B1.50B
Net Income
475.80M727.30M984.80M1.20B1.33B1.25B
EPS
----27.8627.50
EPS Growth
----13.07%-1.28%
Forward PE
13.4513.579.9312.1717.1419.22
Free Cash Flow
406.69M506.28M613.49M834.08M583.20M1.23B
No. Analysts
-----13
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High3.3B
Avg3.2B
Low3.1B

Revenue Growth

Revenue Growth202620272028
High
5.1%
Avg
1.7%
Low
-1.5%

EPS Forecast

EPS202620272028
High32.68
Avg27.50
Low24.93

EPS Growth

EPS Growth202620272028
High
17.3%
Avg
-1.3%
Low
-10.5%